Even so, we also noticed HDACi achieved better tumor-suppression efficacy than AKT inhibition in both in vitro and in vivo, in both single and combinatorial treatment (Fig. 2 and Fig. 6), suggesting HDACis might also function through inhibiting signaling pathways other than PI3K/AKT pathway, such as MAPK signaling pathway (Fig. 3B). This evidence concerns the gene AKT1 and neoplasm.